SCHEMBL51077

SCHEMBL51077

Cc1cnnn1-c1cc(F)ccc1CNC(=O)c1nc2n(c(=O)c1OCc1ccccc1)CC1CCN2CC1

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MYC P01106 6/20 0.34
WDR5 P61964 6/20 0.34
TRPV1 Q8NER1 2/20 0.34
KDM1A O60341 4/20 0.33
P2RX7 Q99572 3/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
USP2 O75604 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
GPR6 P46095 1/20 0.32
RIPK1 Q13546 1/20 0.32
PDE5A O76074 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL51840 0.89 MYC (0.33) MYCWDR5TRPV1KDM1AP2RX7
SCHEMBL52802 0.86 CYP2C9 (0.39) MYCWDR5TRPV1P2RX7CYP2C9
SCHEMBL52140 0.85 P2RX7 (0.35) TRPV1KDM1AP2RX7MAOAMAOB
SCHEMBL52371 0.84 KDM1A (0.35) TRPV1KDM1AP2RX7L3MBTL1MAOA
SCHEMBL52370 0.83 KDM1A (0.34) TRPV1KDM1AP2RX7L3MBTL1MAOA
SCHEMBL52756 0.83 KDM1A (0.37) TRPV1KDM1AP2RX7MAOAMAOB
SCHEMBL51927 0.82 LMNA (0.46) L3MBTL1ALDH1A1CYP2C9TSHRPDE5A
SCHEMBL52029 0.80 CYP1A2 (0.40) ALDH1A1CYP1A2PDE5A
SCHEMBL2528775 0.79 MYC (0.33) MYCWDR5P2RX7PDE5A
SCHEMBL52158 0.75 CYP2C9 (0.39) MYCWDR5P2RX7CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280981-B1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-04-23 EP disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-8129398-B2 HIV integrase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-03-06 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
US-20090253677-A1 HIV Integrase Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-10-08 US disclosed
WO-2009117540-A1 BRIDGED HETEROCYCLES AS HIV INTEGRASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253677-A1 HIV Integrase Inhibitors DNTT, POLB, UNG MYC 2229/4885WDR5 2782/4885TRPV1 4767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.